Skip to main content
. Author manuscript; available in PMC: 2019 Dec 15.
Published in final edited form as: Clin Cancer Res. 2018 Aug 20;24(24):6408–6420. doi: 10.1158/1078-0432.CCR-17-3265

Figure 4. Inhibition of Akt and mTOR pathways in R191-treated cells.

Figure 4.

BCWM.1 (A) and MWCL-1 cells (B) were treated with R191 for 24 hours, and the expression and/or phosphorylation status of the indicated proteins was examined by Western blotting using β-actin as a loading control. Cell lines were generated that expressed either a dominant-negative Akt-AAA construct or a constitutively-active Akt-DD construct, which impacted downstream Akt signaling as would be predicted (C).BCWM.1 and MWCL-1 cells expressing these mutants were treated with R191 for 24 hours, and cell viability was evaluated (D).Data are expressed as the means ± SD for samples in triplicate, and “*” indicates p-values <0.009, while “**” indicates p-values <0.003, and “***” indicates p-values <0.0001.